--- title: "Bioxcel Therap | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 206 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/286553828.md" datetime: "2026-05-15T11:08:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286553828.md) - [en](https://longbridge.com/en/news/286553828.md) - [zh-HK](https://longbridge.com/zh-HK/news/286553828.md) --- # Bioxcel Therap | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 206 K Revenue: As of FY2026 Q1, the actual value is USD 206 K, missing the estimate of USD 381.49 K. EPS: As of FY2026 Q1, the actual value is USD -0.54. EBIT: As of FY2026 Q1, the actual value is USD -6.236 M. #### Product Revenues BioXcel Therapeutics, Inc. reported product revenues of $206 thousand for the first quarter of 2026, an increase from $168 thousand for the same period in 2025. #### Cost of Goods Sold Cost of Goods Sold for the first quarter of 2026 was $283 thousand, compared to $14 thousand for the first quarter of 2025, primarily due to higher charges for reserves for excess or obsolete inventory. #### Research and Development (R&D) Expenses Research and Development expenses decreased to $2,955 thousand for the first quarter of 2026 from $4,554 thousand in the same period of 2025, mainly due to the completion of the SERENITY At-Home pivotal Phase 3 safety trial in 2025. #### Selling, General and Administrative (SG&A) Expenses Selling, General and Administrative expenses increased to $7,191 thousand for the first quarter of 2026, up from $5,699 thousand in the first quarter of 2025, primarily driven by an increase in professional fees. #### Total Operating Expenses Total operating expenses were $10,429 thousand for the first quarter of 2026, compared to $10,267 thousand for the same period in 2025. #### Loss from Operations BioXcel Therapeutics, Inc. reported an operating loss of - $10,223 thousand for the first quarter of 2026, slightly higher than the operating loss of - $10,099 thousand for the same period in 2025. #### Interest Expense, net Net interest expense was $4,198 thousand for the first quarter of 2026, compared to $3,993 thousand for the same period in 2025. #### Interest Income Interest income was - $211 thousand for the first quarter of 2026, compared to - $279 thousand for the same period in 2025. #### Other (income) expense, net Other (income) expense, net was - $1,519 thousand for the first quarter of 2026, compared to - $6,559 thousand for the same period in 2025. #### Net Loss BioXcel Therapeutics, Inc. reported a net loss of - $12,691 thousand for the first quarter of 2026, an increase from a net loss of - $7,254 thousand for the same period in 2025. #### Net Loss Per Share Net loss per share - basic and diluted was - $0.54 for the first quarter of 2026, compared to - $1.50 for the same period in 2025. #### Weighted Average Shares Outstanding Weighted average shares outstanding - basic and diluted were 23,571 thousand for the first quarter of 2026, compared to 4,834 thousand for the same period in 2025. #### Cash and Cash Equivalents and Restricted Cash Cash and cash equivalents and restricted cash totaled $17,180 thousand as of March 31, 2026. #### Total Assets Total assets were $34,025 thousand as of March 31, 2026, down from $44,916 thousand as of December 31, 2025. #### Total Liabilities Total liabilities were $139,568 thousand as of March 31, 2026, a slight decrease from $140,379 thousand as of December 31, 2025. #### Total Stockholders’ Equity (Deficit) Total stockholders’ equity (deficit) was - $105,543 thousand as of March 31, 2026, compared to - $95,463 thousand as of December 31, 2025. #### Outlook / Guidance BioXcel Therapeutics, Inc. announced that the FDA accepted its supplemental New Drug Application (sNDA) for IGALMI® for at-home use, with a PDUFA target action date of November 14, 2026. The company is exploring strategic options for the IGALMI franchise and preparing for its commercial launch in the at-home setting. Additionally, BioXcel Therapeutics, Inc. continues to focus on the potential of BXCL501 in Alzheimer’s dementia. ### Related Stocks - [BTAI.US](https://longbridge.com/en/quote/BTAI.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [TDK publishes 2026 annual report for fiscal year ended March 31, 2026](https://longbridge.com/en/news/287131408.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)